PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1092217
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1092217
The global Exosome Research market is estimated to be worth $186.7 million in 2021. Exosome Research market is expected to expand at an 38.1% CAGR during the forecast period.
Exosomes are produced during the maturation of endosomes. The production of intraluminal vesicles is caused by endosomes budding inward forming multivesicular bodies (MVBs) (ILVs). Exosomes derived from cow milk are being used to deliver therapeutic compounds to patients suffering from lung and breast cancer. Because of their tiny size, indigenous character, and capacity to traverse biological barriers, exosomes produced from specific body regions are intriguing candidates for anti-cancer vaccinations due to better passive targeting. As a result, as the number of cancer cases in hospitals rises, so does the demand for exosomes in diagnostics and therapies. Exosomes contain proteins and genetic markers that can be used to predict disease prognosis and progression.
The expanding financing for life sciences research, the rising global prevalence of cancer, and the growing interest in exosome-based procedures are all driving this industry forward. Market expansion will be aided by an increase in the number of research grants and initiatives offered by various research organizations. Methods for effective isolation and characterization of exosomal vesicles are being developed in projects. Exosomes' involvement in several tasks, as well as the availability of a wide range of routes, are predicted to fuel research in the field, resulting in income production. In the next years, an increase in research funding is also predicted to bolster the industry. The increased demand for exosomes is directly related to the rising prevalence of cancer patients. According to the GLOBOCAN 2020 report, 19.29 million people worldwide are living with cancer, with this figure anticipated to climb over the next two decades. Furthermore, the American Cancer Society predicts that 1,898,160 new instances of cancer will be identified in the United States in 2021, with 608,570 people dying from the disease in 2020.
Exosome Research Market is segmented by products & services, disease indication, application, end-user, and geography. Based on application, the biomarkers segment dominates the global exosome research market in 2021. Exosomes are used as a non-invasive biomarker as well as a medication delivery system for chemotherapeutic sensitization. This has resulted in more research and development on these messengers. Exosomes may be isolated from a variety of biofluids, including blood, urine, and saliva, which has bolstered their usage as disease biomarkers. Exosomes are also being employed in producing vaccines against the COVID-19 virus. The need for exosomes is increasing during the current COVID-19 epidemic, which is propelling the industry forward. Exosomes are extracellular vesicles with a diameter of 30-120 nanometers that have a role in a variety of diseases. Exosomes are released by virus-infected cells and are thought to aid in infection by transmitting viral components such as viral-derived miRNAs and proteins. Exosomes also carry virus receptors, which make recipient cells vulnerable to virus infection.
The global Exosome Research market is fairly competitive with a presence of a large number of international and national players. Some of the major players in the market are Thermo Fisher Scientific, System Biosciences, Bio-Techne, Lonza, and QIAGEN N.V., among others. Industry players are relying on product approvals, product launches, mergers, and acquisitions to gain a significant share of the global Exosome Research market. For instance, In November 2021, Lonza acquired Codiak BioSciences, an exosome manufacturing facility located in the US, pioneering the development of exosome-based therapeutics.
The scope of this report covers the market by its major segments, which include as follows: